Novo Nordisk’s Pill-and-Pipeline Equation Runs Through a Revenue Check

Novo Nordisk’s November report will test whether growth from a new version of Wegovy can offset fading sales of established medicines—and whether the company can support its full-year outlook with commercial results. The nine-month figures are due on 4 November; research updates later in the month may add to the longer-term story, but cannot substitute for evidence in the accounts.

Analysts expect the Wegovy pill to generate 4.6 billion DKK in third-quarter 2026 revenue. They forecast a 2.1% decline for injectable Wegovy, while Ozempic sales are expected to fall 13.7% to 26.5 billion DKK. Rybelsus revenue is also forecast to decrease. The figures point to diverging fortunes across the portfolio, rather than a uniform recovery.

For the broader obesity-treatment business, the consensus is 24.9 billion DKK in revenue, up 18.2%. Analysts also expect adjusted operating profit of 28.4 billion DKK and a gross margin of 80.2%, compared with 76.1% in the third quarter of 2025. A stronger profit result would not, by itself, demonstrate a broad-based recovery in demand.

The 2026 revenue outlook is another key measure. An increase, an unchanged forecast or a reduction would each carry a different message, and none has been announced in the source material. Investors will also need to assess the reasoning behind the guidance, including how much it relies on demand for existing products. Novo Nordisk’s planned US list-price cuts should be considered separately: from 1 January 2027, list prices for Wegovy are set to fall by around 50% and those for Ozempic by around 35%. Those changes are not the same as already-realised selling prices or established revenue effects.

After the 4 November results, the AASLD meeting runs from 5–9 November. Novo Nordisk has announced twelve scientific contributions, including clinical and real-world research on semaglutide and work on investigational drug Efruxifermin. Those presentations could inform the longer-term outlook, but they address a different question from whether near-term sales expectations are holding up.

The next scheduled research update is ObesityWeek, from 14–17 November, where the company has announced 26 contributions. They include results on low-dose CagriSema from REDEFINE 9, data on the Wegovy pill in routine care, and findings from STEP Young in children. Real-world treatment data may help put the pill’s use into practice in perspective, but it should not be mistaken for reported sales.

CagriSema also comes with an important qualification. An exploratory post-hoc analysis of REDEFINE-1, presented around two weeks ago, associated treatment in women with an average weight loss of 25% after 68 weeks. CagriSema remains an investigational drug: the analysis does not establish approval or a future revenue contribution, and the forthcoming low-dose results will need to be assessed on their own merits.

The order of evidence matters for shareholders. First comes the revenue outlook and the balance between new Wegovy pill sales and weakness in established products; then come the clinical updates that may shape future expectations. Research can strengthen a business case supported by commercial performance, but it cannot establish that performance on its own.